The enhanced anti-tumor response with agents blocking the SIRPα-CD47 interaction may arise from the activation of multiple DC subsets (i.e. shown by increased CD86 expression) that is seen within the spleen (data not shown) [14]. This evidence concerns the gene CD47 and neoplasm.